rs28941784 — MMAB Arg186Trp (R186W)

MMAB Arg186Trp — When the Final Step in Vitamin B12 Activation Fails

Vitamin B12 that arrives in your mitochondria is not yet useful. Before it can power the critical enzyme methylmalonyl-CoA mutase (MCM)¹¹ methylmalonyl-CoA mutase (MCM)
MCM converts methylmalonyl-CoA to succinyl-CoA, channelling odd-chain fatty acids and certain amino acids into the citric acid cycle, the vitamin must be converted to its active mitochondrial cofactor form — adenosylcobalamin (AdoCbl). That final conversion step is performed by MMAB, also called ATP:cob(I)alamin adenosyltransferase or cblB. MMAB acts as both the enzyme that synthesises AdoCbl and the chaperone that loads it directly onto MCM. When MMAB fails, the entire methylmalonyl pathway stalls, and methylmalonic acid accumulates to toxic levels throughout the body.

The Arg186Trp (R186W) variant — c.556C>T in the MMAB transcript — is the most frequently identified pathogenic allele in MMAB, accounting for 29–33% of all pathogenic alleles in European and North American cblB cohorts²² 29–33% of all pathogenic alleles in European and North American cblB cohorts
GeneReviews: Isolated Methylmalonic Acidemia, NBK1231. Homozygous or compound heterozygous individuals develop cblB-type methylmalonic acidemia (MMA), an organic acidemia that typically presents as a metabolic emergency in early infancy. Heterozygous carriers have one functional MMAB copy and are unaffected, but carry a 50% chance of passing the variant to each child.

The Mechanism

MMAB forms a homotrimeric complex; each subunit contributes a cobalamin-binding pocket and an ATP-binding site at the trimer interface. Arginine at position 186 sits at the subunit-subunit interface³³ Arginine at position 186 sits at the subunit-subunit interface
Zhang et al. 2006, PMID 16439175: Arg186 contributes to both AdoCbl binding and proper protein folding at the interface region, where it makes contacts critical for both ATP/cobalamin coordination and structural integrity of the trimer. The substitution of the positively charged arginine with the bulky, aromatic tryptophan disrupts these contacts and destabilises the protein severely enough that no MMAB protein is detectable on Western blot in patient cells — making R186W a protein-null allele rather than a partial-function variant. This is distinct from p.Arg191Trp, another common MMAB variant that produces a detectable protein with residual enzymatic activity. The complete absence of MMAB protein means neither AdoCbl synthesis nor chaperone-mediated cofactor delivery to MCM can occur, creating a total block in the mitochondrial branch of B12 metabolism.

The Evidence

The pathogenic significance of R186W was established in the foundational cblB characterisation study by Lerner-Ellis et al. 2006 (PMID 16410054)⁴⁴ Lerner-Ellis et al. 2006 (PMID 16410054), which analysed mutations in 35 cblB patients and found R186W in 33% of all pathogenic alleles — a striking enrichment in patients of European ancestry. The associated biochemical study by Zhang et al. 2006 (PMID 16439175)⁵⁵ Zhang et al. 2006 (PMID 16439175) confirmed absent MMAB protein and complete loss of ATR activity for R186W, contrasting with the partial activity retained by R191W.

The most comprehensive dataset comes from Forny et al. 2021 (PMID 34796408)⁶⁶ Forny et al. 2021 (PMID 34796408), which characterised bi-allelic MMAB variants in 97 cblB patients. p.(Arg186Trp) appeared in 57 alleles — the single most frequent allele in the entire cohort. R186W homozygotes showed no cobalamin responsiveness and early-onset disease consistent with a complete null, while individuals carrying the p.(Gln234*) allele on at least one chromosome showed variable onset and some biochemical B12 responsiveness. This study established the clinical rule: the disease severity in cblB is dominated by the less-severe of the two alleles, and R186W is among the most severe.

Clinical outcomes in cblB type MMA are among the worst in the organic acidemias. GeneReviews data⁷⁷ GeneReviews data
NBK1231; Horster et al. 2007, PMID 17661827 cite approximately 50% mortality with median age of death around 2.9 years, and chronic renal failure in ~66% of survivors. Without treatment, neonates presenting with metabolic crisis from R186W homozygosity have an extremely poor prognosis.

Practical Implications

For homozygous or compound heterozygous individuals (AA genotype): cblB MMA is detected by expanded newborn screening (NBS) in most countries via elevated propionylcarnitine (C3). Confirmation requires urine organic acids (elevated methylmalonic acid), plasma amino acids, and MMAB sequencing. R186W homozygotes are not expected to respond to hydroxocobalamin treatment — unlike cblA patients or cblB patients carrying at least one Q234* allele — so management focuses on metabolic diet (low-protein, natural protein restriction with medical formula), carnitine supplementation, and vigilant monitoring for renal function, metabolic decompensation triggers, and neurological outcomes. Emergency metabolic protocols must be established at diagnosis; infections and catabolism precipitate acute crises.

For heterozygous carriers (AG genotype): one functional MMAB allele fully compensates and carriers are metabolically unaffected. The clinical relevance is reproductive: each pregnancy of two carrier parents carries a 25% chance of an affected child. The European carrier frequency for all MMAB pathogenic variants collectively is estimated around 1 in 200–300, with R186W specifically elevated among Northern and Central European populations.

Interactions

The most clinically important interaction is compound heterozygosity with other MMAB pathogenic variants. R186W paired with p.(Arg191Trp) produces a phenotype similar to R186W homozygosity — both are non-responsive alleles. R186W paired with p.(Gln234*) may allow partial cobalamin responsiveness because Q234* is a less-severe allele; in this case a hydroxocobalamin trial is worthwhile even though R186W itself is null. The clinical rule — severity is set by the milder of the two alleles — means the partner allele's functional class determines the treatment approach and prognosis.

MMAB deficiency operates downstream in a pathway that includes MMAA (cblA), MMUT (the MCM enzyme itself), and upstream cobalamin transport and processing genes (TCN2, LMBRD1, ABCD4, MMADHC). Defects anywhere in this pathway elevate methylmalonic acid; MMAB deficiency specifically affects only the mitochondrial AdoCbl synthesis step and not the methylation branch (no homocystinuria, unlike cblC/D/F/J/X defects).